Ovarian cryopreservation (OC) aims to preserve ovarian cortical tissue with primordial follicles before the start of gonadotoxic treatment, such as chemoradiotherapy, recognized as causing premature ovarian failure and sterility. On an ethical level, clear information concerning this risk and its potential prevention and treatment is obviously necessary, and this has in France been a legal obligation since 2006. The objective of OC is to transplant the ovarian cortex after remission to restore fertility. Six human live births have been described since 2004 after OC and autografting. 1 OC is now widely performed by numerous teams, although the cases reported in the literature are still limited. In some cancers, the ovary may be contaminated by malignant cells with a potential risk of relapse if autografting is performed. 2 In CML, leukemic cells are characterized by the chimeric Bcr-Abl transcript, which can be accurately quantified using the standardized RQ-PCR method. Treatment of CML relies on Imatinib, but allo-SCT remains the only definite curative treatment especially in younger patients. 3 With regard to ovarian autografting, none of the published cases have shown detectable disease with conventional techniques before transplantation. In CML, however, the use of RQ-PCR allows us to detect a very low tumor burden with a high sensitivity of up to 0.001%. Here, we illustrate this particular situation and discuss its implications in the context of ovarian transplantation and cancer.
An 18-year-old nulliparous woman was diagnosed with chronic phase CML with a high Sokal index. After 6 months of imatinib, the patient failed to achieve a major cytogenetic response, and a geno-identical allo-SCT with standard myeloablative regimen was planned. She was referred to our reproductive medicine unit for evaluation of fertility preservation, considering the high risk of gonadotoxicity. In vitro fertilization was not possible as she had no partner and the decision for OC was finally taken. After 2 months, before allo-SCT and OC, hormonal markers of ovarian follicular reserve were normal and disease evaluation showed a 0.025% Bcr-Abl/Abl ratio.
Whole right ovariectomy was performed by laparoscopy as previously described by our team. 4 We voluntarily chose not to perform a bilateral ovariectomy in view of the small potential for resumption of ovarian function after a treatment considered to be sterilizing. Biopsies of the ovarian cortex and medulla were studied both by standard cytology and by RQ-PCR. There were no detectable tumor cells on routine histology, whereas RQ-PCR detected a small copy number of Bcr-Abl transcripts in the ovarian medulla (0.026%) and also in the cortex, below the limit of quantification of the technique (0.001%). At 2 years after allo-SCT, the patient was in complete molecular response and the question of ovarian transplantation arose.
In this case, routine histological assessment showed no malignant cells and tumor cells were only detected in the ovary by RQ-PCR. There were two hypotheses: first, blood contamination was possible; at the same time, the RQ-PCR in blood was close to the same level of transcript and the medulla (that is the hilum of the ovary) is highly vascularized compared with the cortex. This could explain the difference in transcript level shown between the medulla and cortex. Second, the presence of malignant cells in tissue is possible, as extramedullary disease including ovarian localisation have already been described in CML and other hematological malignancies. Nevertheless, ovarian disease is very rare and limited to advanced stages of CML (that is, blastic phase with ovarian chloroma 5 ). The type of technique used does not allow the location of the CML cells to be ascertained (that is, blood vs tissue) and distinguishing between these two hypotheses is not possible. Recently, Meirow et al. 6 reported one similar case but did not discuss its significance.
Whatever the origin of these CML cells, the option of ovarian transplantation in this setting is highly questionable: on the one hand, transplanting tumor cells in an immunocompromised recipient is a matter of concern and the ovary has been described as a potential sanctuary site after frontline treatment. In vivo studies have shown that the graft of ovarian tissue from AKR mice with lymphoma could transmit the disease to healthy AKR mice 7 and xenograft models gave conclusive, even if more controversial, results. 8 On the other hand, we know that engraftment of tumor cells depends on the tumor burden infused. This has been shown after auto-SCT 9 and the number of clonogenic cells in this case will be very low. Moreover, in the allo-SCT setting, the graft-vs-tumor effect, highly effective in CML patients, might also have a protective role 3 after ovarian transplantation. To sum up, in the CML setting, the associated risk of relapse if ovarian transplantation is performed is limited. In our opinion, ovarian transplantation could be proposed for this patient and similar cases but clear information for the patient on the risk/benefit ratio and integration in a carefully controlled clinical evaluation is mandatory. It is noted that this would not be appropriate in other diseases such as hormonedependent tumors, including breast cancer.
Minimal residual disease (MRD) monitoring is currently used extensively in hematological malignancies and solid tumors and the question of MRD before OC will increase. The current practice for OC uses morphological and histological evaluation of the ovarian medulla and fragments of the cortex before freezing to avoid possible transplantation of the ovary containing metastatic disease. Nevertheless, techniques, sensitivity and their potential use on ovarian tissue vary greatly from one indication to another, and the use of blood MRD as a surrogate marker for potential ovarian contamination is open to discussion. This will limit the use of OC if all positive patients are excluded. The use of direct techniques on ovarian tissue seems the more promising approach but implies that some patients will be ovariectomized but will never be considered for ovarian autograft if tumor cells were detected. The best schedule for each disease must be defined to preserve the maximum ovarian function and to limit the risk of potential residual disease when OC is undertaken. Moreover, the risk of disease recurrence related to ovarian autografting cannot be evaluated currently as the number of cases is too small. 1 We also need to keep in mind that some other questions remain unsolved regarding the effects of imatinib on cryopreserved ovarian tissue and relapse risk related to immunomodulation during pregnancy. In conclusion, the hope of pregnancy is an important issue for young women treated for cancer with sterilizing therapies, and collaboration between hematologists and specialized gynecological teams needs to be encouraged to answer these questions and to give the best information for patients.
